Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application

被引:14
|
作者
Skrzypiec-Spring, Monika [1 ]
Haczkiewicz, Katarzyna [2 ]
Sapa, Agnieszka [3 ]
Piasecki, Tomasz [4 ,5 ]
Kwiatkowska, Joanna [1 ]
Ceremuga, Ireneusz [6 ]
Wozniak, Mieczyslaw [3 ]
Biczysko, Wieslawa [7 ]
Kobierzycki, Christopher [2 ]
Dziegiel, Piotr [2 ,8 ]
Podhorska-Okolow, Marzenna [2 ]
Szelag, Adam [1 ]
机构
[1] Wroclaw Med Univ, Dept Pharmacol, Jana Mikulicza Radeckiego 2, PL-50368 Wroclaw, Poland
[2] Wroclaw Med Univ, Dept Histol & Embryol, Wroclaw, Poland
[3] Wroclaw Med Univ, Dept Med Lab Diagnost, Wroclaw, Poland
[4] Wroclaw Univ Environm & Life Sci, Dept Epizootiol, Wroclaw, Poland
[5] Wroclaw Univ Environm & Life Sci, Clin Bird & Exot Anim, Wroclaw, Poland
[6] Wroclaw Med Univ, Dept Med Biochem, Wroclaw, Poland
[7] Poznan Univ Med Sci, Dept Clin Pathomorphol, Poznan, Poland
[8] Univ Sch Phys Educ, Dept Physiotherapy, Wroclaw, Poland
关键词
carvedilol; metalloproteinase-2; autoimmune myocarditis; acute myocarditis; ISCHEMIA-REPERFUSION INJURY; OXIDATIVE STRESS; INFLAMMATORY CARDIOMYOPATHY; HEART-FAILURE; RATS; DIAGNOSIS; IMPROVES; TARGET;
D O I
10.1177/1074248417725058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Acute myocarditis is a potentially lethal inflammatory heart disease that frequently precedes the development of dilated cardiomyopathy and subsequent heart failure. At present, there is no effective standardized therapy for acute myocarditis, besides the optimal care of heart failure and arrhythmias in accordance with evidence-based guidelines and specific etiology-driven therapy for infectious myocarditis. Carvedilol has been shown to be cardioprotective by reducing cardiac pro-inflammatory cytokines present in oxidative stress in certain heart diseases. However, effects of carvedilol administration in acute myocarditis with its impact on matrix metalloproteinases' (MMPs) activation have not been elucidated. Methods and Results: Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks. In comparison to untreated rats (n = 8) with induced myocarditis, carvedilol significantly prevented the left ventricle enlargement and/or systolic dysfunction depending on the dose in study groups. Performed zymography showed enhanced MMP-2 activity in untreated rats, while carvedilol administration reduced alterations. This was accompanied by prevention of troponin I release and myofilaments degradation in cardiac muscle tissue. Additionally, severe inflammatory cell infiltration was detected in the nontreated group. Carvedilol in all doses tested, had no impact on severity of inflammation. The severity of inflammation did not differ between study groups and in relation to the untreated group. Conclusions: The protective effects of carvedilol on heart function observed in the acute phase of experimental autoimmune myocarditis seem to be associated with its ability to decrease MMP-2 activity and subsequently prevent degradation of myofilaments and release of troponin I while not related to suppression of inflammation.
引用
收藏
页码:89 / 97
页数:9
相关论文
共 50 条
  • [1] Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and-9 in experimental atherosclerosis
    Wu, Tao-Cheng
    Chen, Yung-Hsiang
    Leu, Hsin-Bang
    Chen, Yuh-Lien
    Lin, Feng-Yen
    Lin, Shing-Jong
    Chen, Jaw-Wen
    FREE RADICAL BIOLOGY AND MEDICINE, 2007, 43 (11) : 1508 - 1522
  • [2] The role of matrix metalloproteinase-2 in the immunopathogenesis of experimental autoimmune encephalomyelitis in the mouse
    Esparza, J
    Kruse, MA
    Lee, JYM
    Madri, JA
    FASEB JOURNAL, 2004, 18 (05): : A1115 - A1115
  • [3] Matrix Metalloproteinase-2 Inhibition in Acute Ischemia-Reperfusion Heart Injury-Cardioprotective Properties of Carvedilol
    Skrzypiec-Spring, Monika
    Urbaniak, Joanna
    Sapa-Wojciechowska, Agnieszka
    Pietkiewicz, Jadwiga
    Orda, Alina
    Karolko, Bozena
    Danielewicz, Regina
    Bil-Lula, Iwona
    Wozniak, Mieczyslaw
    Schulz, Richard
    Szelag, Adam
    PHARMACEUTICALS, 2021, 14 (12)
  • [4] Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy
    Fukami, Kei
    Yamagishi, Sho-ichi
    Coughlan, Melinda T
    Harcourt, Brooke E
    Kantharidis, Phillip
    Thallas-Bonke, Vicki
    Okuda, Seiya
    Cooper, Mark E
    Forbes, Josephine M
    DIABETOLOGY & METABOLIC SYNDROME, 2014, 6
  • [5] Ramipril inhibits AGE-RAGE-induced matrix metalloproteinase-2 activation in experimental diabetic nephropathy
    Kei Fukami
    Sho-ichi Yamagishi
    Melinda T Coughlan
    Brooke E Harcourt
    Phillip Kantharidis
    Vicki Thallas-Bonke
    Seiya Okuda
    Mark E Cooper
    Josephine M Forbes
    Diabetology & Metabolic Syndrome, 6
  • [6] Role of matrix metalloproteinase-2 in the cardioprotective effect of ischaemic postconditioning
    Donato, Martin
    D'Annunzio, Veronica
    Buchholz, Bruno
    Miksztowicz, Veronica
    Lorenzo Carrion, Cristina
    Valdez, Laura B.
    Zaobornyj, Tamara
    Schreier, Laura
    Wikinski, Regina
    Boveris, Alberto
    Berg, Gabriela
    Gelpi, Ricardo J.
    EXPERIMENTAL PHYSIOLOGY, 2010, 95 (02) : 274 - 281
  • [7] Moderate inhibition of myocardial matrix metalloproteinase-2 by ilomastat is cardioprotective
    Bencsik, Peter
    Paloczi, Janos
    Kocsis, Gabriella F.
    Pipis, Judit
    Belecz, Istvan
    Varga, Zoltan V.
    Csonka, Csaba
    Goerbe, Aniko
    Csont, Tamas
    Ferdinandy, Peter
    PHARMACOLOGICAL RESEARCH, 2014, 80 : 36 - 42
  • [8] The interrelationship of α4 integrin and matrix metalloproteinase-2 in the pathogenesis of experimental autoimmune encephalomyelitis
    Graesser, D
    Mahooti, S
    Haas, T
    Davis, S
    Clark, RB
    Madri, JA
    LABORATORY INVESTIGATION, 1998, 78 (11) : 1445 - 1458
  • [9] Keratoconus: Matrix metalloproteinase-2 activation and TIMP modulation
    Smith, VA
    Matthews, FJ
    Majid, MA
    Cook, SD
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2006, 1762 (04): : 431 - 439
  • [10] Implication of the activation of matrix metalloproteinase-2 on the metastasis in breast
    Oh, SJ
    Hong, MK
    Kim, KM
    Yoo, SJ
    Jung, SS
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 316 - 316